Next-generation sequencing: A change of paradigm in molecular diagnostic validation

Journal of Pathology

Volumn 234, Issue 1, 2014, Pages 5-10

  Salto Tellez, Manuel ^a   Gonzalez De Castro, David ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

next generation sequencing (NGS); technology; validation

Indexed keywords

DNA;

BIOINFORMATICS; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DNA SEQUENCE; GENE SEQUENCE; HUMAN; LIMIT OF DETECTION; MOLECULAR DIAGNOSIS; NEXT GENERATION SEQUENCING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; TASK PERFORMANCE; TURNAROUND TIME; VALIDATION STUDY; DNA MUTATIONAL ANALYSIS; ECONOMICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; MUTATION; PROCEDURES; REPRODUCIBILITY; TIME FACTOR;

DNA MUTATIONAL ANALYSIS; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LIMIT OF DETECTION; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; TIME FACTORS; VALIDATION STUDIES AS TOPIC;

EID: 84905858372     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4365     Document Type: Review

References (10)

1. Tothill RW, Li J, Mileshkin L, et al., Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. J Pathol 2013; 231: 413-423.
2. Witkowski L, Lalonde E, Zhang J, et al., Familial rhabdoid tumour 'avant la lettre'-from pathology review to exome sequencing and back again. J Pathol 2013; 231: 35-43.
3. Catherwood MA, Maxwell P, Waugh DJ, et al., Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis., McCourt CM, McArt DG, Mills K, (eds). PLoS One 2013; 8 (7): e69604.
4. Frampton GM, Fichtenholtz A, Otto GA, et al., Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31: 1023-1031.
5. Pritchard CC, Salipante SJ, Koehler K, et al., Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn 2014; 16: 56-67.
6. Mattocks CJ, Morris MA, Matthijs G, et al., A standardized framework for the validation and verification of clinical molecular genetic tests. Eur J Hum Genet 2010; 18: 1276-1288.
7. Lindeman NI, Cagle PT, Beasley MB, et al., Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 2013; 15: 415-453.
8. André F, Bachelot T, Commo F, et al., Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 2014; ii: S1470-2045(13) 70611-9; doi: 10.1016/S1470-2045(13)70611-9.
9. Berry DA,. Adaptive clinical trials in oncology. Nat Rev Clin Oncol 2011; 9 (4): 199-207.
10. http://www.wadsworth.org/labcert/TestApproval/forms/NextGenSeq-ONCO- Guidelines.pdf